Dystrophin Deficiency Leads to Genomic Instability in Human Pluripotent Stem Cells via NO Synthase-Induced Oxidative Stress.
Sarka JelinkovaPetr FojtikAneta KohutovaAleksandra ViloticLenka MarkováMartin PeslTereza JurakovaMiriama KrutaJan VrbskyRenata GaillyovaIveta ValáškováIvan FrákAlain LacampagneGiancarlo FortePetr DvorakAlbano C MeliVladimir RotreklPublished in: Cells (2019)
Recent data on Duchenne muscular dystrophy (DMD) show myocyte progenitor's involvement in the disease pathology often leading to the DMD patient's death. The molecular mechanism underlying stem cell impairment in DMD has not been described. We created dystrophin-deficient human pluripotent stem cell (hPSC) lines by reprogramming cells from two DMD patients, and also by introducing dystrophin mutation into human embryonic stem cells via CRISPR/Cas9. While dystrophin is expressed in healthy hPSC, its deficiency in DMD hPSC lines induces the release of reactive oxygen species (ROS) through dysregulated activity of all three isoforms of nitric oxide synthase (further abrev. as, NOS). NOS-induced ROS release leads to DNA damage and genomic instability in DMD hPSC. We were able to reduce both the ROS release as well as DNA damage to the level of wild-type hPSC by inhibiting NOS activity.
Keyphrases
- duchenne muscular dystrophy
- dna damage
- pluripotent stem cells
- nitric oxide synthase
- reactive oxygen species
- stem cells
- endothelial cells
- muscular dystrophy
- nitric oxide
- crispr cas
- oxidative stress
- induced pluripotent stem cells
- dna repair
- wild type
- cell death
- high glucose
- embryonic stem cells
- newly diagnosed
- end stage renal disease
- hydrogen peroxide
- prognostic factors
- copy number
- signaling pathway
- mesenchymal stem cells
- drug induced
- smoking cessation
- bone marrow
- cell therapy
- big data
- patient reported outcomes
- dna methylation
- cell fate